 Connection
Viralkumar Shah to Insulin Glargine
This is a "connection" page, showing publications Viralkumar Shah has written about Insulin Glargine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.870 |
|
|
|
-
Shah VN, Dex T, Meneghini L, Rodrigues A, Polonsky WH. Treatment satisfaction and time in range after 16?weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 May; 27(5):2523-2530.
Score: 0.841
-
FrÃas JP, Ratzki-Leewing A, Dex T, Meneghini L, Rodrigues A, Shah VN. Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 Apr; 27(4):2173-2182.
Score: 0.839
-
Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Mukherjee B, Shah VN. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther. 2020 02; 22(2):85-95.
Score: 0.593
-
Shah VN, Al-Karadsheh A, Barnes C, Mandry J, Nakhle S, Wernicke-Panten K, Kramer D, Schmider W, Pierre S, Teichert L, Rotthaeuser B, Mukherjee B, Bailey TS. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial. Diabetes Obes Metab. 2024 02; 26(2):540-547.
Score: 0.192
-
Shah VN. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med. 2021 02 25; 384(8):e26.
Score: 0.160
-
Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Miossec P, Mukherjee B, Shah VN. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial. Diabetes Technol Ther. 2020 07; 22(7):516-526.
Score: 0.150
-
Shah VN, Moser EG, Blau A, Dhingra M, Garg SK. The future of basal insulin. Diabetes Technol Ther. 2013 Sep; 15(9):727-32.
Score: 0.095
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|